ITMCTR2200005750尚未招募未知
Effects of Xinkeshu Tablets on anxiety and depression, quality of life and recurrent cardiovascular events in patients with acute coronary syndrome with anxiety comorbidity and depression
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 89（—）
- 性别
- All
入选标准
- •1. Diagnosed inpatients with ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina pectoris (UA) in line with the clinical diagnostic criteria of the International Society of Cardiology, with stable condition before discharge include;
- •2. In a state of anxiety and comorbid depression: PHQ-9 score = 10 points and GAD-7 score = 10 points;
- •3. Enrollment age: age > 18 years old, gender is not limited;
- •4. Subjects gave informed consent and participated voluntarily;
排除标准
- •(1) Taking psychotropic drugs within one week; taking cardiovascular-related Chinese herbal medicines or proprietary Chinese medicines, or Chinese herbal medicines or proprietary Chinese medicines for improving sleep within one week; anti-anxiety and depression drugs and insomnia drugs must be taken;
- •(2) Pregnant and lactating women;
- •(3) Severe primary heart, liver, lung, kidney, blood or serious diseases affecting their survival, such as tumor or AIDS; abnormal liver and kidney function, serum ALT and/or AST > 1×ULN (upper limit); , Cr, Urea>1×ULN (upper limit);
- •(4) Patients with decompensated respiratory insufficiency, myasthenia gravis and sleep apnea syndrome;
- •(5) Patients with severe epilepsy who cannot give fully informed consent due to mental disorders;
- •(6) Suspect or have a history of alcohol or drug abuse;
- •(7) According to the judgment of the investigator, other diseases that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment, are likely to cause loss to follow-up;
- •(8) Allergic constitution, such as those with a history of allergies to two or more drugs or food; or those who are known to be allergic to the ingredients of this medicine;
- •(9) Subjects who have participated in or are participating in clinical trials of other drugs within three months before enrollment;
- •(10) Patients with serious diseases such as malignant tumors, severe chronic obstructive pulmonary disease, and angle-closure glaucoma;
- •(11) Have a clear history of mental illness (bidirectional disorder, schizophrenia), suicidal tendencies, and language and communication disorders;
- •(12) limb paralysis due to cerebrovascular sequelae, and other serious diseases are not expected to complete the 1-year follow-up;
研究者
相似试验
已完成
不适用
What is the effect of Xinkeshu tablets added to usual treatment on the function of the circulatory system in patients with coronary artery disease and high blood pressure?ISRCTN22691979Shandong Wohua Pharmaceutical Co Ltd120
尚未招募
2 期
The effect of Chinese herbal medicine on sleep quality in stressed people suffering from insomniaInsomniaACTRN12617000351314niversity of Technology Sydney20
Unknown
4 期
Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina PectorisCoronary Heart DiseaseStable AnginaNCT04270279Guang'anmen Hospital of China Academy of Chinese Medical Sciences120
招募中
1 期
Clinical effects of Xingxiao Pill in the treatment of cancercancerITMCTR2000004184Dongfang Hospital, Beijing University of Chinese Medicine
招募中
4 期
Clinical study of Shenshao tablet on improving exercise tolerance of patients with chronic ischemic heart failure (qi deficiency and blood stasis syndrome)chronic ischemic heart failure (qi deficiency and blood stasis syndrome)ITMCTR2100004280The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine